BTK and mantle cell lymphoma: MiR-223-3p could directly inhibit conserved helix-loop-helix ubiquitous kinase (CHUK) and further decrease the expression of NF-κB, thereby reversing Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib resistance in MCL [96].